Shu Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shu Kang has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Qingchang Li
Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110001, China
1 shared publication - Xinyu Zheng
Lab 1, Cancer Institute, China Medical University, Shenyang, Liaoning 110001, P.R. China
1 shared publication - Yu Kang
Department of Breast Surgery, the First Affiliated Hospital, China Medical University, North Nanjing Street 155, Shenyang 110001, P.R. China
1 shared publication
Latest Publications
- Open Access
- 13 March 2014
- Published by Springer Nature in European Journal of Medical Research
- Vol. 19 (1) , 14
Mixed epithelial and mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast: a case report
Metaplastic breast carcinoma (MBC) is an uncommon malignancy characterized by the co-existence of two or more cellular types, commonly a mixture of epithelial and mesenchymal components. A case of a female patient aged 46 years with MBC (carcinosarcoma) is presented, including mammographic, ultrasonic, gross examination, and pathological findings. After undergoing modified radical mastectomy of the left breast and subsequent six courses of adjuvant chemotherapy and endocrine therapy, the patient is now doing well with no recurrence and metastasis. Conventional treatments for invasive ductal carcinoma (IDC) may appear to be less effective. Patients with MBC would be appropriate candidates for innovative or targeted therapy regimens.
- 13 March 2014
- Published by Springer Nature in European Journal of Medical Research
- Vol. 19 (1) , 14
Open AccessMixed epithelial and mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast: a case report
Metaplastic breast carcinoma (MBC) is an uncommon malignancy characterized by the co-existence of two or more cellular types, commonly a mixture of epithelial and mesenchymal components. A case of a female patient aged 46 years with MBC (carcinosarcoma) is presented, including mammographic, ultrasonic, gross examination, and pathological findings. After undergoing modified radical mastectomy of the left breast and subsequent six courses of adjuvant chemotherapy and endocrine therapy, the patient is now doing well with no recurrence and metastasis. Conventional treatments for invasive ductal carcinoma (IDC) may appear to be less effective. Patients with MBC would be appropriate candidates for innovative or targeted therapy regimens.